UK, AI-powered biotech Healx is joining forces with Boehringer Ingelheim to identify indications related to rare neurological diseases.
The companies will work together on a project that will leverage Healx’ comprehensive AI-based drug discovery platform, Healnet, and expertise in rare diseases and pharmacology to identify potential new indications for assets from Boehringer’s pipeline.
Healx said its data analysis and technological capabilities will be used to direct Boehringer’s efforts in prioritising selected indications for further research, with the firm’s AI platform to play a key part in the collaborative effort.
“Harnessing BI’s expertise for drug development, especially in rare neurological conditions, in combination with our AI-powered drug discovery platform, will enable faster identification of potential new treatments,” said Dr Tim Guilliams, Healx’ founder and chief executive, commenting on the partnership.
Further details on the deal were not disclosed.
